379 related articles for article (PubMed ID: 15668188)
1. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
2. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
3. Fibrinolytic inhibitor levels and polymorphisms in Behçet disease and their association with thrombosis.
Ricart JM; Ramón LA; Vayá A; España F; Santaolaria ML; Todolí J; Castelló R; Fontcuberta J; Estellés A
Br J Haematol; 2008 May; 141(5):716-9. PubMed ID: 18341631
[TBL] [Abstract][Full Text] [Related]
4. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
5. The plasma levels of activated thrombin activatable fibrinolysis inhibitor and thrombomodulin in Behçet disease and their association with thrombosis.
Donmez A; Aksu K; Aydin H; Keser G; Cagirgan S; Doganavsargil E; Tombuloglu M
Thromb Res; 2010 Sep; 126(3):207-10. PubMed ID: 20542541
[TBL] [Abstract][Full Text] [Related]
6. Increased advanced oxidation protein products in Behçet's disease: a new activity marker?
Yazici C; Köse K; Caliş M; DemIr M; Kirnap M; Ateş F
Br J Dermatol; 2004 Jul; 151(1):105-11. PubMed ID: 15270878
[TBL] [Abstract][Full Text] [Related]
7. Association of genotypes of thrombin-activatable fibrinolysis inhibitors with thrombotic microangiopathies--a pilot study.
Sucker C; Hetzel GR; Farokhzad F; Dahhan F; Schmitz M; Kurschat C; Grabensee B; Maruhn-Debowski B; Zotz R; Scharf R
Nephrol Dial Transplant; 2007 May; 22(5):1347-50. PubMed ID: 17327284
[TBL] [Abstract][Full Text] [Related]
8. Levels of soluble E-selectin in patients with active Behcet's disease.
Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M
Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451
[TBL] [Abstract][Full Text] [Related]
9. Plasma thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 levels in inflammatory bowel disease.
Koutroubakis IE; Sfiridaki A; Tsiolakidou G; Coucoutsi C; Theodoropoulou A; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2008 Sep; 20(9):912-6. PubMed ID: 18794606
[TBL] [Abstract][Full Text] [Related]
10. Identification of polymorphisms in the 5'-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis.
Franco RF; Fagundes MG; Meijers JC; Reitsma PH; Lourenço D; Morelli V; Maffei FH; Ferrari IC; Piccinato CE; Silva WA; Zago MA
Haematologica; 2001 May; 86(5):510-7. PubMed ID: 11410415
[TBL] [Abstract][Full Text] [Related]
11. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
Ermantas N; Guldiken S; Demir M; Tugrul A
Clin Appl Thromb Hemost; 2010 Oct; 16(5):568-73. PubMed ID: 19959491
[TBL] [Abstract][Full Text] [Related]
12. [Thrombin activatable fibrinolysis inhibitor (TAFI) in allergic asthma patients].
Kemona-Chetnik I; Kowal K; Kucharewicz I; Pampuch A; Bodzenta-Lukaszyk A
Przegl Lek; 2006; 63(12):1281-5. PubMed ID: 17642140
[TBL] [Abstract][Full Text] [Related]
13. Plasma homocysteine level and uveitis in Behçet's disease.
Okka M; Oztürk M; Kockar MC; Bavbek N; Rasier Y; Gunduz K
Isr Med Assoc J; 2002 Nov; 4(11 Suppl):931-4. PubMed ID: 12455183
[TBL] [Abstract][Full Text] [Related]
14. Do hemorheological alterations play any role in the development of thrombotic events in Behçet's disease?
Vayá A; Ricart J; Todolí J; Micó L; Contreras T; Aznar J
Clin Hemorheol Microcirc; 2004; 30(3-4):411-4. PubMed ID: 15258375
[TBL] [Abstract][Full Text] [Related]
15. Plasma activity of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever.
Sonmez M; Aydin K; Durmus A; Sucu N; Yilmaz M; Akdogan E; Koksal I; Ovali E; Omay SB
J Infect; 2007 Aug; 55(2):184-7. PubMed ID: 17418898
[TBL] [Abstract][Full Text] [Related]
16. Decreased erythrocyte deformability in Behçet's disease.
Usküdar O; Erdem A; Demiroğlu H; Dikmenoğlu N
Clin Hemorheol Microcirc; 2005; 33(2):89-94. PubMed ID: 16151256
[TBL] [Abstract][Full Text] [Related]
17. Circulated activated platelets and increased platelet reactivity in patients with Behçet's disease.
Akar S; Ozcan MA; Ateş H; Gürler O; Alacacioglu I; Ozsan GH; Akkoç N; Ozkan S; Demirkan F; Onen F
Clin Appl Thromb Hemost; 2006 Oct; 12(4):451-7. PubMed ID: 17000890
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
19. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement.
Durmazlar SP; Ulkar GB; Eskioglu F; Tatlican S; Mert A; Akgul A
Int J Dermatol; 2009 Mar; 48(3):259-64. PubMed ID: 19261013
[TBL] [Abstract][Full Text] [Related]
20. Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome.
Erdoğan M; Karadeniz M; Alper GE; Tamsel S; Uluer H; Cağlayan O; Saygili F; Yilmaz C
Exp Clin Endocrinol Diabetes; 2008 Mar; 116(3):143-7. PubMed ID: 18350479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
